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inTrOdUCTiOn
Healthcare is at the verge of a revolution. We are entering the era of “precision medicine” in which 
prevention and treatment of diseases will be tailored according to the characteristics of each patient 
and the in-depth characterization of the pathologic processes underlying human disorders (1). This 
novel approach of medical care will include, among others, powerful computational analyses of large 
sets of biological and clinical data collected via electronic health records and mobile health technolo-
gies. Indeed, risk to develop specific disorders, and chance to respond to particular preventive or 
therapeutic measures, will be determined by individual profiles emerging from the integrated col-
lection of clinical, genetic, environmental, and lifestyle data. This new knowledge will result in novel 
diagnostic and therapeutic tools, such as genomics-based tests, interventional imaging techniques, 
innovative medical devices, and cell-based or gene-based therapies, in addition to more efficient and 
safer (bio)pharmaceuticals.
In this context, medicine will converge more and more with other life sciences, physical sciences 
and engineering sciences, which would require new models of collaborative innovation. Furthermore, 
innovation in healthcare will necessitate more than scientific and technological advances. In order 
to fill the gap between lab bench and patient bedside, new approaches for product development, 
regulation, market access (pricing/reimbursement), and patient access and adoption will become 
increasingly important.
Translational medicine can be defined as the interdisciplinary science that will cover this con-
tinuum, from basic research to preclinical and clinical research, development of new medicines 
and medical devices, and ultimately patient-centric care. Interestingly, this is not a unidirectional 
path as very often it might be necessary to go back to research when unexpected findings are made 
after introduction of a new product on the market. The holistic approach inherent to translational 
medicine is essential to address the major public health challenges that our societies are facing, such 
as Alzheimer’s dementia, the diabetes’ epidemics, antimicrobial resistance, or the development of 
novel cancer therapies.
Irrespective of their specific role in the healthcare system of the future, physicians and other 
healthcare providers, scientists, managers, regulators, and policy makers will need knowledge in 
translational medicine to be able to contribute to interdisciplinary endeavors. They will also have 
to develop the skills necessary to address organizational, business, and management issues in this 
complex sector.
Academia represents an ideal environment to develop the educational and training programs 
needed to prepare the next generation of healthcare professionals to this challenge. Indeed, uni-
versities and other academic institutions offer advanced expertise in the multiple domains to be 
considered for the setup of cross-disciplinary research and education. Academic programs should be 
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developed in close collaboration with the industrial sector, which 
is already investing in continuous professional development and 
lifelong learning activities relevant to translational medicine.
Herein, we underline key elements of precision medicine that 
need to be considered in the development of interdisciplinary 
educational programs.
deVelOPMenT OF a neW TaXOnOMY 
OF diSeaSeS
In medical practice, the most commonly used taxonomy system 
is the International Classification of Diseases established more 
than 100 years ago by the World Health Organization. Although 
this classification resulted in significant medical advances and the 
development of several blockbuster drugs, it is not fit-for-purpose 
for precision medicine. In order to tailor therapies according 
to molecular changes underlying pathological processes, it is 
essential to integrate clinical data with information derived 
from genomics and other “omics” sciences, i.e., proteomics, 
metabolomics, and transcriptomics. Imaging data should also be 
included in the new classification of diseases. The cancer field is 
currently the one in which the benefit of such “systems medicine” 
approach to optimize the treatment of patients is best established. 
The development of this new taxonomy of diseases will depend 
on the exploitation of “Big Data” that will have to be appropriately 
collected through different tools including electronic health 
records. In this respect, the development and use of standards 
will be the key to ensure data interoperability (2). Likewise, it will 
be essential to ensure data accuracy and prevent publication of 
unreliable information.
deVelOPinG neW TrialS deSiGnS
There is a clear need to develop new types of clinical trials to 
address the limitations of classical randomized controlled trials 
that are characterized by rigid protocols. Adaptive trial designs 
elicit particular interest from investigators, industry, and patients 
because they offer opportunities to prospectively plan protocol’s 
modifications on the basis of accumulated data, without jeopard-
izing the validity of the study’s conclusions. Possible adaptations 
may involve drug dosage, allocation of treatments, addition or 
deletion of treatment arms, combination of therapies, adjustment 
of statistical hypotheses, etc. Indeed, sophisticated statistical 
analyses and powerful computing platforms are necessary to 
ensure the reliability of these adaptive trial designs which help 
to select most promising therapies early, reduce the number of 
patients enrolled, and overall speed up the process of develop-
ment. Precision medicine will greatly benefit from adaptive 
designs, especially those that use biomarkers for enrichment in a 
specific patient population for early detection of disease.
MOVinG reGUlaTOrY SCienCe 
FOrWard
Regulators are expected to make recommendations on therapies 
according to the balance between the benefits they provide and 
the potential adverse events they might induce. Until recently, 
regulators were merely considered as gatekeepers of patient 
safety. Nowadays, they must become active partners in the 
efficient implementation of precision medicine. This will require 
adaptations of regulatory policies and guidelines according to 
the so-called “regulatory science,” which includes novel tools to 
assess drug safety preclinically and new approaches to assess drug 
effectiveness under real-life conditions. Furthermore, regulatory 
bodies will need to adapt their licensing schemes in order to build 
new pathways to bring innovative therapies to patients more 
efficiently (3). This is the focus of a remarkable multi-stakeholder 
international collaboration, the Medicines Adaptive Pathways to 
Patients (MAPPS) initiative (http://bit.ly/1W7GLAt).
enSUrinG PaTienT aCCeSS
One of the greatest challenges to introduce precision medicine 
in the standard of care is to make it affordable to individuals and 
society. The ongoing debate about the prices of the new curative 
therapies for hepatitis C and the immune check point inhibitors, 
which dramatically improve the treatment of melanoma and 
other cancers, illustrate the need for new approaches to assess 
the balance between cost and value in healthcare. The develop-
ment of targeted therapies is complex not only scientifically but 
also from an economic standpoint. With the advent of tailored 
care, numbers of patients eligible for breakthrough therapies and 
corresponding market size are markedly reduced. As the era of 
blockbusters is over, industry has to adopt new schemes to get 
return on their investments in research and development and to 
make pharmaceutical innovation profitable. In parallel, payers 
must ensure the sustainability of healthcare costs. Methodologies 
that facilitate adjustment of drug pricing on the basis of objec-
tive criteria will need to be developed, especially those based on 
patient outcomes. Clearly, health economics and management 
must be included in the interdisciplinary programs designed to 
move precision medicine forward (4).
PaTienT CenTriCiTY
The assessment of health outcomes will be essential to capture the 
value of precision medicine and make it sustainable. Patients have 
a key role to play in this assessment, as recognized by industry 
and regulators. What patients expect from new therapies must 
be considered in the design of clinical studies. Of particular 
importance is their evaluation of the balance between risks and 
benefits, even if this dimension needs to integrate the impact of 
a self-centered perspective  –  inherent to the patient’s position. 
Research, education, and training in social and behavioral sci-
ences will be important to ensure appropriate communication 
and dialog with patients about the key questions related to health 
outcomes and effectiveness of new therapies.
COnClUdinG reMarKS
Collaboration between healthcare stakeholders will be essential 
to address the complex scientific, regulatory, societal, and eco-
nomic challenges related to precision medicine. This will require 
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reconciling and aligning the interests of private for-profit 
companies and publicly funded not-profit institutions around 
patients’ needs and expectations. Recent years have witnessed the 
establishment of a number of public private partnerships and 
research consortia with this objective, including the Innovative 
Medicines Initiative (IMI) in Europe, the Critical Path Initiative, 
the Foundation for the NIH and the Accelerating Medicines 
Partnership in the United States, and CQDM in Canada. They 
represent the natural instruments to assemble the critical 
mass of expertise and resources necessary to implement the 
joint endeavors that should result in new therapies for major 
unmet needs,  including brain disorders, antimicrobial resist-
ance, diabetes, immune-inflammatory diseases, and cancer. 
Although meaningful results have already been achieved, future 
advances will depend on innovative educational programs that 
will provide the next generation of healthcare professionals with 
sound and robust bases for interdisciplinary patient-focused 
approaches and will develop their mindset for collaboration (4). 
Scientific journals have an important role in this respect. As an 
open access journal with digital platforms that aim at catalyz-
ing collaboration, Frontiers in Medicine is fully committed to 
contribute to this endeavor.
aUThOr COnTriBUTiOnS
MG conceived and wrote the paper.
reFerenCeS
1. Collins FD, Varmus H. A new initiative on precision medicine. N Engl J Med 
(2015) 372:793–5. doi:10.1056/NEJMp1500523
2. Kush R, Goldman M. Responsible data sharing. N Engl J Med (2014) 370:2161–3. 
doi:10.1056/NEJMp1401444 
3. Eichler HG, Baird LG, Barker R, Bloechl-Daum B, Børlum-Kristensen F, Brown 
J, et  al. From adaptive licensing to adaptive pathways: delivering a flexible 
life-span approach to bring new drugs to patients. Clin Pharmacol Ther (2015) 
97:234–46. doi:10.1002/cpt.59 
4. Kurpinski K, Johnson T, Kumar S, Desai T, Li S. Mastering translational 
 medicine: interdisciplinary education for a new generation. Sci Transl Med 
(2014) 6:218fs2. doi:10.1126/scitranslmed.3006858 
Conflict of Interest Statement: The author declares that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2016 Goldman. This is an open-access article distributed under 
the terms of the Creative Commons Attribution License (CC BY). The use, 
distribution or reproduction in other forums is permitted, provided the orig-
inal author(s) or licensor are credited and that the original publication in 
this journal is cited, in accordance with accepted academic practice. No use, 
distribution or reproduction is permitted which does not comply with these 
terms.
